Search
                    Ohio Paid Clinical Trials
A listing of 3204  clinical trials  in Ohio  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            2329 - 2340 of 3204
        
                Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Study of DB-1310 in Advanced/Metastatic Solid Tumors
                                
            
            
        Recruiting
                            
            
                This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/03/2025
            
            Locations: Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati, Ohio         
        
        
            Conditions: Advanced Solid Tumor
        
            
        
    
                
                                    Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are:
1. Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD
2. Efficacy of CAST in reducing care partner burden among care partne...  Read More             
        
        
    Gender:
                ALL
            Ages:
                60 years and above
            Trial Updated:
                03/03/2025
            
            Locations: Ohio University, Athens, Ohio         
        
        
            
        
    
                
                                    Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
                                
            
            
        Recruiting
                            
            
                One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/03/2025
            
            Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio         
        
        
            Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
        
            
        
    
                
                                    Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
                                
            
            
        Recruiting
                            
            
                The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 18 years
            Trial Updated:
                03/03/2025
            
            Locations: Cincinnati Children's Hospital, Cincinnati, Ohio         
        
        
            Conditions: Partial Epilepsy
        
            
        
    
                
                                    Poly-omic Predictors of Symptom Duration and Recovery for Adolescent Concussion
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to identify changes in salivary micro ribonucleic acid (miRNA) levels that are predictive of symptom duration and character following mild traumatic brain injury (mTBI) in children.             
        
        
    Gender:
                ALL
            Ages:
                Between 13 years and 18 years
            Trial Updated:
                03/03/2025
            
            Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio         
        
        
            Conditions: Concussion, Mild
        
            
        
    
                
                                    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
                                
            
            
        Recruiting
                            
            
                Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                03/03/2025
            
            Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Feasibility of Neural Feedback for Lower Limb Amputees
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the effectiveness of providing sensation of the missing limb to individuals with lower limb loss, including above and below knee amputees. The approach involves delivering small electrical currents directly to remaining nerves via implanted stimulating electrodes. These small electrical currents cause the nerves to generate signals that are then transferred to your brain similar to how information about the foot and lower limb used to be transferred to yo...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/03/2025
            
            Locations: Louis Stokes VA Medical Center, Cleveland, Ohio         
        
        
            Conditions: Amputation
        
            
        
    
                
                                    Feasibility Study of CBCT for IGRT in Cancer Patients
                                
            
            
        Recruiting
                            
            
                Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.
Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                02/28/2025
            
            Locations: The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio         
        
        
            Conditions: Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer, Genito Urinary Cancer, Gastrointestinal Cancers
        
            
        
    
                
                                    A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to evaluate the impact of SCThrive (a behavioral self-management intervention) on patient activation, self-management behaviors, daily functioning, and emergency room visits in 260 adolescents and young adults with sickle cell disease (SCD) ages 13-21 receiving care at 1 of 4 pediatric SCD clinics.
The main question\[s\]it aims to answer are:
* Does SCThrive improve patient activation?
* Does SCThrive improve self-management behaviors, daily functioning, and...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 13 years and 21 years
            Trial Updated:
                02/28/2025
            
            Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio         
        
        
            Conditions: Anemia, Sickle Cell
        
            
        
    
                
                                    Head and Neck Cancer Patient Symptom and Oncologic Outcomes
                                
            
            
        Recruiting
                            
            
                This trial investigates a new approach using a mobile three-dimensional (3D) scanning application for volumetric measurement of the head and neck region in patients with head and neck lymphedema. Lymphedema is the buildup of extra lymph fluid in tissues that causes swelling. Accurate volumetric measurements of swelling are crucial to the diagnosis of lymphedema and to monitoring response to therapy and disease progression over time. A mobile 3D surface scanning application may help doctors measu...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                02/28/2025
            
            Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio         
        
        
            Conditions: Lymphedema of the Head and Neck
        
            
        
    
                
                                    Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients with Persistent Disease After Induction
                                
            
            
        Recruiting
                            
            
                This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stoppi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                02/28/2025
            
            Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio         
        
        
            Conditions: Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia
        
            
        
    
                
                                    Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                02/28/2025
            
            Locations: GSK Investigational Site, Cleveland, Ohio         
        
        
            Conditions: Neoplasms
        
            
        
    